



DT06 Rec'd PCT/PTO 06 AUG 2002

PATENT

Case Docket No. WWELL60.001APC

Date: August 2, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Küpper, et al.
Appl. No. : 10/069,382
Filed : February 19, 2002
For : GENE TRANSFER VECTOR
SYSTEM DERIVED FROM
COXSACKIE VIRUSES
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to: United States Patent and Trademark
Office, P.O. Box 2327, Arlington, VA 22202, on

August 2, 2002
(Date)

Mark R. Benedict, Reg. No. 44,531

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Mark R. Benedict
Registration No. 44,531
Attorney of Record



WWELL60.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Küpper, et al.)	Group Art Unit: Unknown
)	
App. No.	:	10/069,382)	
)	
Filed	:	February 19, 2002)	
)	
For	:	GENE TRANSFER VECTOR)	
		SYSTEM DERIVED FROM)	
		COXSACKIE VIRUSES)	
)	
Examiner	:	Unknown)	
)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/2/02

By: Mark R. Benedict

Mark R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. WWELL60.001APC	APPLICATION NO. 10/069,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kupper, et al.	
		FILING DATE February 19, 2002	GROUP Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1.	Barr, E., et al. (1994) Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. <i>Gene Therapy</i> 1:51-58.
	2.	Nabel, E. G., et al. (1990) Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall. <i>Science</i> 249:1285-1288.
	3.	Nabel, E. G., et al. (1989) Recombinant Gene Expression <i>in Vivo</i> Within Endothelial Cells of the Arterial Wall. <i>Science</i> 244:1342-1344.
	4.	Felgner, P. L., et al. (1987) Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. <i>PNAS</i> 84:7413-7417.
	5.	Kandolf, R., and Hofschneider, P. H. (1985) Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: Full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. <i>PNAS</i> 82:4818-4822.
	6.	Klump, W. M., et al. (1990) Complete Nucleotide Sequence of Infectious Coxsackievirus B3 cDNA: Two Initial 5' Uridine Residues Are Regained during Plus-Strand RNA Synthesis. <i>J. Virol.</i> 64(4):1573-1583.
	7.	Porter, D. C., et al. (1995) Encapsulation of Poliovirus Replicons Encoding the Complete Human Immunodeficiency Virus Type 1 gag Gene by Using a Complementation System Which Provides the P1 Capsid Protein in <i>trans</i> . <i>J. Virol.</i> 69(3):1548-1555.
	8.	Porter, D. C., et al (1996) Release of Virus-Like Particles from Cells Infected with Poliovirus Replicons Which Express Human Immunodeficiency Virus Type 1 Gag. <i>J. Virol.</i> 70(4):2643-2649.

O:\DOCS\MXG\MXG-1475.DOC:vb
073102

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	